Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
less decrease » mean decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
less decrease » mean decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2421
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2422
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2423
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2424
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2425
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2426
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2427
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2428
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
2429
Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff
Published 2025“…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
-
2430
Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff
Published 2025“…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
-
2431
Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif
Published 2025“…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
-
2432
Image 3_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff
Published 2025“…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
-
2433
The epidemiology and gene mutation characteristics of pyrazinamide-resistant <i>Mycobacterium tuberculosis</i> clinical isolates in Southern China
Published 2025“…This difference in the <i>rpsA</i> mutation rate was statistically significant (<i>P = 0.001</i>, chi-square test). …”
-
2434
-
2435
-
2436
Participant characteristics.
Published 2025“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
-
2437
-
2438
-
2439
Uganda 2023 NCD risk factor STEPS survey data.
Published 2025“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
-
2440
Uganda 2014 NCD risk factor STEPS survey data.
Published 2025“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”